Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 987 across all filing types
Latest filing 2013-02-11 Major Shareholding Noti…
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
SC 13D
Major Shareholding Notification
2013-02-11 English
SCHEDULE 13D
Major Shareholding Notification
2013-02-08 English
SC 13D
Major Shareholding Notification
2013-02-08 English
FORM 3 -
Director's Dealing
2013-02-01 English
424B3
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed pursuant to the Securities Exchange Act of 1934. It announces the appointment of Alison Lawton as Chief Operating Officer and other changes in senior management positions. The content focuses on management changes, including details about the new COO's background, employment terms, and related press release. There are no financial statements, earnings data, or other report types present. The document is not a proxy statement, annual report, or earnings release. Therefore, it fits the category of Board/Management Information (MANG). The document length (13,588 characters) supports it being a full report rather than a brief announcement or certification. Hence, the classification is MANG with high confidence.
2013-01-02 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 28, 2012. The main content is about the departure and appointment of certain officers, specifically the election of Alison Lawton as Chief Operating Officer and changes in other executive roles. There is no financial data or report content, but rather announcements of management changes. This fits the category of Board/Management Information (MANG). The document length is 5371 characters, which is sufficient to contain detailed information about management changes. Therefore, the classification is MANG with high confidence.
2013-01-02 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.